Better Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022

Rhea-AI Summary

Better Therapeutics, Inc. (NASDAQ: BTTX) will release its second quarter 2022 financial results on August 11, 2022, before market opening. A conference call will be held at 8:30 a.m. ET on the same day to provide a business update. Better Therapeutics specializes in prescription digital therapeutics aimed at addressing cardiometabolic diseases through nutritional cognitive behavioral therapy (nCBT). Their FDA-regulated software-based solutions target conditions like type 2 diabetes and heart disease to improve patient health and reduce healthcare costs.

Positive

• Developing FDA-regulated digital therapeutics for cardiometabolic diseases.
• Focus on reducing healthcare costs through behavioral therapy solutions.

Negative

• None.

SAN FRANCISCO--(BUSINESS WIRE)-- Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced it will release its second quarter 2022 financial results before the market opens on Thursday, August 11, 2022. Management will host a conference call and webcast to provide a business update at 8:30 a.m. ET / 5:30 a.m. PT on Thursday, August 11, 2022.

To access the conference call, please register at: https://register.vevent.com/register/BI6da59cc90fdb42a39adb1f216262cac7. Upon registering, each participant will be provided with call details and access codes. All participants are encouraged to join 10 minutes prior to the start time. The live webcast may be accessed by visiting the event link at: https://edge.media-server.com/mmc/p/zcn84y83. Following the webcast, a replay of the webcast may be accessed from the Presentations & Events page in the Investors section of the Better Therapeutics corporate website at: investors.bettertx.com.

About Better Therapeutics

Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.

For more information visit: bettertx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005116/en/

Investor Relations:

Mark Heinen

IR@bettertx.com

Media:

Ryan McKenna at Real Chemistry

rmckenna@realchemistry.com

Source: Better Therapeutics, Inc.

FAQ

When will Better Therapeutics announce its Q2 2022 financial results?

Better Therapeutics will release its Q2 2022 financial results on August 11, 2022.

What is the focus of Better Therapeutics' digital therapeutics?

Better Therapeutics focuses on developing prescription digital therapeutics for cardiometabolic diseases.

What time is the conference call for Better Therapeutics' business update?

The conference call for Better Therapeutics' business update will be held at 8:30 a.m. ET on August 11, 2022.

What is the stock ticker for Better Therapeutics?

The stock ticker for Better Therapeutics is BTTX.